RenovoRx Statistics
Total Valuation
RenovoRx has a market cap or net worth of $46.54 million. The enterprise value is $35.04 million.
Important Dates
The next estimated earnings date is Wednesday, November 12, 2025, before market open.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RenovoRx has 36.65 million shares outstanding. The number of shares has increased by 95.52% in one year.
| Current Share Class | 36.65M |
| Shares Outstanding | 36.65M |
| Shares Change (YoY) | +95.52% |
| Shares Change (QoQ) | +16.50% |
| Owned by Insiders (%) | 3.34% |
| Owned by Institutions (%) | 9.61% |
| Float | 30.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 57.08 |
| Forward PS | 17.21 |
| PB Ratio | 4.41 |
| P/TBV Ratio | 4.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 52.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.61, with a Debt / Equity ratio of 0.02.
| Current Ratio | 8.61 |
| Quick Ratio | 8.15 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -107.11% and return on invested capital (ROIC) is -69.70%.
| Return on Equity (ROE) | -107.11% |
| Return on Assets (ROA) | -54.82% |
| Return on Invested Capital (ROIC) | -69.70% |
| Return on Capital Employed (ROCE) | -93.06% |
| Revenue Per Employee | $66,200 |
| Profits Per Employee | -$1.07M |
| Employee Count | 10 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.79% in the last 52 weeks. The beta is 1.23, so RenovoRx's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | +8.79% |
| 50-Day Moving Average | 1.17 |
| 200-Day Moving Average | 1.18 |
| Relative Strength Index (RSI) | 56.75 |
| Average Volume (20 Days) | 579,524 |
Short Selling Information
The latest short interest is 198,095, so 0.54% of the outstanding shares have been sold short.
| Short Interest | 198,095 |
| Short Previous Month | 134,441 |
| Short % of Shares Out | 0.54% |
| Short % of Float | 0.66% |
| Short Ratio (days to cover) | 0.91 |
Income Statement
In the last 12 months, RenovoRx had revenue of $662,000 and -$10.66 million in losses. Loss per share was -$0.36.
| Revenue | 662,000 |
| Gross Profit | 416,000 |
| Operating Income | -11.25M |
| Pretax Income | -8.05M |
| Net Income | -10.66M |
| EBITDA | n/a |
| EBIT | -11.25M |
| Loss Per Share | -$0.36 |
Full Income StatementBalance Sheet
The company has $12.31 million in cash and $260,000 in debt, giving a net cash position of $12.05 million or $0.33 per share.
| Cash & Cash Equivalents | 12.31M |
| Total Debt | 260,000 |
| Net Cash | 12.05M |
| Net Cash Per Share | $0.33 |
| Equity (Book Value) | 10.64M |
| Book Value Per Share | 0.29 |
| Working Capital | 11.84M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$10.31 million and capital expenditures -$14,000, giving a free cash flow of -$10.32 million.
| Operating Cash Flow | -10.31M |
| Capital Expenditures | -14,000 |
| Free Cash Flow | -10.32M |
| FCF Per Share | -$0.28 |
Full Cash Flow StatementMargins
| Gross Margin | 62.84% |
| Operating Margin | -1,699.09% |
| Pretax Margin | -1,610.88% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RenovoRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -95.52% |
| Shareholder Yield | -95.52% |
| Earnings Yield | -22.65% |
| FCF Yield | -21.92% |
Analyst Forecast
The average price target for RenovoRx is $7.50, which is 490.55% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.50 |
| Price Target Difference | 490.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 394.31% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RenovoRx has an Altman Z-Score of -0.83 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.83 |
| Piotroski F-Score | 1 |
